📇 Rhumatologue ·

M OLIVIER RIOU

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Référence presse grand public
Cité 5 fois dans les médias — pédagogie reconnue

Rhumatologue

RPPS 10001105781

7ans d'exercice (thèse 2019)

🇫🇷 Publications académiques françaises (8)🎓 1 thèse dirigée

✨ Génération du profil synthétique IA en cours…

Thèses universitaires

Individualisation de la prise en charge en radiothérapie par la recherche de biomarqueurs immunologiques de réponse au traitement : application au cancer du col utérin
2019
Study of predictive immune biomarkers for radiotherapy personalization: application to locally advanced cervix cancer

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Articles de presse (5)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

Montpellier : l’ICM inaugure son nouvel IRM 3 Tesla - Actu.fr

📰 Actu.fr · 16/05/2024

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxONnlOcVEzektVWlE0WWFoMHJBM0RCbEFqYlZtZm9XS2lWZ2lxNGlsbkhRVDRvdERHaEdLaWhLczRlSXkzY2s2dzM5N2pIQ0x3U3drcmo2UTFwRF9jdUVYT29BTlhMT1ZNS2VxOTRodEl4WTdtb0U4X0ZHdEtDWU8wUVJ2OGxuX0ZkbGtKd1VrS1BaeWc1b3pnTzBGd3F4QmJNS2psVjh5bW1mcVU?oc=5" target="_bla

L'ICM se dote d'une nouvelle IRM à la pointe de la technologie pour une meilleure prise en charge du cancer à Montpellier - Midi Libre

📰 Midi Libre · 15/05/2024

<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxQQjNBQTFSX0ljYmFKbTE3dFlWQW04LTR4SGl3VTFLZmN1WE9lbVF2VUtNOENZVnJfa2ZoalBxT1JPMHo1OVBucVc4VDByNHJ4OWN5NS15SHVZLWtJaDJwMHgyMXZJV3g3VHdOSDcyZ2lrYWJnNUV2Qm5VTnpSR0xyTTVaQkVfWE9aYjgzcTFEQjFKc0EybkFzMjV1U1BUcWhvQTA0eXdaWE9vb3hqUm8xMERFMDRZdk5pNH

Pierre Olivier Rious - MNP.ca

📰 MNP.ca · 03/06/2021

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9UNHY4VFVKRURMZnpXTXptTDgwTVRlSkNtMEh6MjJRblhLN1BHalVlelloVUh2TnhtaFdmekxFT1FYZXV0WUROZnA2VFdVYjk3Y2c1ZUZrUG9DbC0tZmxHeQ?oc=5" target="_blank">Pierre Olivier Rious</a> <font color="#6f6f6f">MNP.ca</font>

Coronavirus. Wallis-et-Futuna, dernier territoire français épargné - Ouest-France

📰 Ouest-France · 21/04/2020

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQT092ck4zR1lIXzZpX0t4NEdISEd6MEVqb1pBem9QU0h4Y0dEMTJtUjRJS3ozSUNoQ2R2ZHItY01nVWNpdkFVazdxSkI0ODZOMzRBa05rNjNmRGk3TkxTUG5GdmJqeTJreDg0T0J5UUR6ci03TDVRVnZ4bWd1ZDZ2dGdvWVZkQVNuWHdobkQ2bERrY3ZOTldsMlZFM05hdDFLc3A1NWlXNWduclUzR1kwS29oUXY5aWNZ?o

Le Wendylan darts club se met à l'heure coréenne - Ouest-France

📰 Ouest-France · 28/02/2013

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWtCR1NEcTZGTnpucHBmOGRXS1JWTGx1dFN0anNOYWhwUjRoRi1PeWN0d3VheGlsRThwc1U4bVRoR1hSVVVGWGNieFExQ2xidWZmV3RvNlQ4dndWbXFmWXY3NVpYYVNzRC1YTDJVMENrbjlkUkU0U0U3TWVRblJhaTNZZ3FGZHBxcjdPSm51UnNFZF9INHJDelJHOG50WW00ekdtVGhHOGtOQQ?oc=5" target="_blan

Top publications · les plus citées

Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial

EBioMedicine · 2015

📚 105 citations🎯 RCR 3.74Top 12% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study

Frontiers in oncology · 2022

📚 31 citations🎯 RCR 2.96Top 16% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

IntroductionStereotactic MR-guided adaptive radiotherapy (SMART) is an attractive modality of radiotherapy for pancreatic tumors. The objectives of this prospective registry study were to report the dosimetric benefits of daily adaptation of SMART and the first clinical results in pancreatic tumors.Materials and MethodsAll patients treated in our center with SMART for a pancreatic tumor were included. Patients were planned for five daily-adapted fractions on consecutive days. Endpoints were acute toxicities, late toxicities, impact of adaptive treatment on target volume coverage and organs at risk (OAR) sparing, local control (LC) rate, distant metastasis-free survival (DMFS), and overall survival (OS).ResultsThirty consecutive patients were included between October 2019 and April 2021. The median dose prescription was 50 Gy. No patient presented grade &gt; 2 acute toxicities. The most frequent grade 1–2 toxicities were asthenia (40%), abdominal pain (40%), and nausea (43%). Daily adaptation significantly improved planning target volume (PTV) and gross tumor volume (GTV) coverage and OAR sparing. With a median follow-up of 9.7 months, the median OS, 6-month OS, and 1-year OS were 14.1 months, 89% (95% CI: 70%–96%), and 75% (95% CI: 51%–88%), respectively, from SMART completion. LC at 6 months and 1 year was respectively 97% (95% CI: 79–99.5%) and 86% (95% CI: 61%–95%). There were no grade &gt; 2 late toxicities. With a median follow-up of 10.64 months, locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC) patients (22 patients) had a median OS, 6-month OS, and 1-year OS from SMART completion of 14.1 months, 76% (95% CI: 51%–89%), and 70% (95% CI: 45%–85%), respectively. Nine patients underwent surgical resection (42.1% of patients with initial LAPC and 33.3% of patients with BRPC), with negative margins (R0). Resected patients had a significantly better OS as compared to unresected patients (p = 0.0219, hazard ratio (HR) = 5.78 (95% CI: 1.29–25.9)).ConclusionSMART for pancreatic tumors is feasible without limiting toxicities. Daily adaptation demonstrated a benefit for tumor coverage and OAR sparing. The severity of observed acute and late toxicities was low. OS and LC rates were promising. SMART achieved a high secondary resection rate in LAPC patients. Surgery after SMART seemed to be feasible and might increase OS in these patients.

Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study

Cancers · 2022

📚 27 citations🎯 RCR 2.35Top 22% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Introduction: Stereotactic MR-guided Adaptive RadioTherapy (SMART) is a novel process to treat pancreatic tumors. We present an update of the data from our prospective registry of SMART for pancreatic tumors. Materials and methods: After the establishment of the SMART indication in a multidisciplinary board, we included all patients treated for pancreatic tumors. Primary endpoints were acute and late toxicities. Secondary endpoints were survival outcomes (local control, overall survival, distant metastasis free survival) and dosimetric advantages of adaptive process on targets volumes and OAR. Results: We included seventy consecutive patients in our cohort between October 2019 and April 2022. The prescribed dose was 50 Gy in 5 consecutive fractions. No severe acute SMART related toxicity was noted. Acute and late Grade ≤ 2 gastro intestinal were low. Daily adaptation significantly improved PTV and GTV coverage as well as OAR sparing. With a median follow-up of 10.8 months since SMART completion, the median OS, 6-months OS, and 1-year OS were 20.9 months, 86.7% (95% CI: (75–93%), and 68.6% (95% CI: (53–80%), respectively, from SMART completion. Local control at 6 months, 1 year, and 2 years were, respectively, 96.8 % (95% CI: 88–99%), 86.5 (95% CI: 68–95%), and 80.7% (95% CI: 59–92%). There was no grade > 2 late toxicities. Locally Advanced Pancreatic Cancers (LAPC) and Borderline Resectable Pancreatic Cancers (BRPC) patients (52 patients) had a median OS, 6-months OS, and 1-year OS from SMART completion of 15.2 months, 84.4% (95% CI: (70–92%)), and 60.5% (95% CI: (42–75%)), respectively. The median OS, 1-year OS, and 2-year OS from initiation of induction chemotherapy were 22.3 months, 91% (95% CI: (78–97%)), and 45.8% (95% CI: (27–63%)), respectively. Twenty patients underwent surgical resection (38.7 % of patients with initially LAPC) with negative margins (R0). Conclusion: To our knowledge, this is the largest series of SMART for pancreatic tumors. The treatment was well tolerated with only low-grade toxicities. Long-term OS and LC rates were achieved. SMART achieved high secondary resection rates in LAPC patients.

Cookies & analyse de trafic

M OLIVIER RIOU

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Direction de thèses

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (5)

Top publications · les plus citées

Publications scientifiques (24) — classées par pathologie

Transversal11

IRM ostéo-articulaire6

Épidémiologie & registres3

Essai clinique3

Gériatrie1

Datasets & protocoles partagés

Partager cette fiche